ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and results of the iCanCare study on second opinions (Abstracts 566 and 6508).

Skin Cancer

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).

Lung Cancer

Palliative Care

Symptom Management

Charles F. von Gunten, MD, PhD

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).

Breast Cancer

Nicholas C. Turner, MD, PhD

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (Abstract LBA502).

Lymphoma

Laurie H. Sehn, MD, MPH

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Sep

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution

First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer

Biomarker Guides Treatment Sequencing Predicts Outcomes in BRAF-Mutated Metastatic Melanoma

High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer

Additional Safety Analysis of DESTINY-Breast05: What Did It Show?